bioAffinity Technologies, Inc.
BIAF · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $9 | $3 | $0 | $0 |
| % Growth | 269.7% | 52,617.1% | – | – |
| Cost of Goods Sold | $6 | $2 | $0 | $0 |
| Gross Profit | $3 | $1 | $0 | -$0 |
| % Margin | 36.1% | 31.3% | 90.3% | – |
| R&D Expenses | $2 | $2 | $2 | $1 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $10 | $7 | $2 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $0 | $0 | $0 |
| Operating Expenses | $12 | $9 | $4 | $2 |
| Operating Income | -$9 | -$8 | -$4 | -$2 |
| % Margin | -95.6% | -314.9% | -83,511.5% | – |
| Other Income/Exp. Net | -$0 | $0 | -$4 | -$4 |
| Pre-Tax Income | -$9 | -$8 | -$8 | -$6 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$9 | -$8 | -$8 | -$6 |
| % Margin | -96.6% | -313.5% | -169,771.2% | – |
| EPS | -22.5 | -27.3 | -54.3 | -25.8 |
| % Growth | 17.6% | 49.7% | -110.5% | – |
| EPS Diluted | -22.5 | -27.3 | -54.3 | -25.8 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $3 | $1 |
| Depreciation & Amortization | $1 | $0 | $0 | $0 |
| EBITDA | -$8 | -$8 | -$6 | -$5 |
| % Margin | -89% | -301.3% | -116,777.7% | – |